Teva and Alvotech get FDA review acceptance for its proposed biosimilar to Eylea
https://seekingalpha.com/news/4409363-teva-and-alvotech-gets-fda-review-acceptance-for-its-proposed-biosimilar-to-eylea?source=feed_sector_healthcare
Feb 18, 2025 -
0
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
https://www.fool.com/investing/2025/02/16/this-stock-is-already-up-51-in-2025-is-it-too-late/?source=iedfolrf0000001
Feb 16, 2025 -
0
Axsome settles Auvelity patent litigation with Teva
https://seekingalpha.com/news/4405591-axsome-settles-auvelity-patent-litigation-with-teva?source=feed_sector_healthcare
Feb 10, 2025 -
0
Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia
https://seekingalpha.com/news/4405439-teva-pharmaceuticals-reports-completion-of-phase-3-trial-for-olanzapine-lai-in-schizophrenia?source=feed_tag_israel
Feb 09, 2025 -
0
Teva fined $500M by EU for disparaging rival MS drug (update)
https://seekingalpha.com/news/4229093-teva-fined-500m-by-european-commission-for-disparaging-rival-ms-drug?source=feed_sector_healthcare
Oct 31, 2024 - The European Commission has fined Israeli drugmaker Teva (TEVA) $500M for disparaging a rival product to its blockbuster multiple sclerosis drug Copaxone. Read more here.
0
Teva settles patent litigation with Amicus
https://seekingalpha.com/news/4175257-teva-settles-patent-litigation-amicus?source=feed_tag_israel
Oct 18, 2024 - Amicus Therapeutics (FOLD) stock gains after the company settled a patent dispute with Teva (TEVA) over a generic version of its best-seller Galafold. Read more here.
0
Teva agrees to pay $425M to settle Copaxone kickback case: DOJ
https://seekingalpha.com/news/4157764-teva-agrees-to-pay-425m-to-settle-copaxone-kickback-case-doj?source=feed_tag_israel
Oct 10, 2024 - Teva (TEVA) has agreed to pay $425M to resolve allegations that it paid kickbacks related to its drug Copaxone through two co-pay assistance foundations. Read more here.
0
TEVA applications for Prolia biosimilar accepted by FDA, EMA
https://seekingalpha.com/news/4157037-teva-applications-for-prolia-biosimilar-accepted-by-fda-ema?source=feed_tag_israel
Oct 08, 2024 - Teva (TEVA) said its market applications have been accepted for review by the FDA and EMA for its proposed biosimilar of Amgen's (AMGN) osteoporosis drug Prolia. Read more here.
0
FTC weighs in on reverse-payment generic delay case involving Gilead, Teva
https://seekingalpha.com/news/4153357-ftc-weighs-reverse-payment-generic-delay-case-involving-gilead-teva?source=feed_sector_healthcare
Sep 25, 2024 - The FTC has filed an amicus brief in a case involving Gilead and Teva's alleged pay-for-delay scheme to delay generic HIV meds, Truvada and Atripla.
0
Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference (Transcript)
https://seekingalpha.com/article/4722088-teva-pharmaceutical-industries-limited-teva-bank-of-america-global-healthcare-conference?source=feed_tag_israel
Sep 19, 2024 - Teva Pharmaceuticals Industries Limited (NYSE:TEVA) Bank of America Global Healthcare Conference September 18, 2024 3:15 AM ETCompany ParticipantsRichard...
0